Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus TIGAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus TIGAN.
COMPAZINE vs TIGAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
TIGAN (trimethobenzamide) acts on the chemoreceptor trigger zone (CTZ) to inhibit emetic stimuli, primarily through antagonism of dopamine D2 receptors, though its exact mechanism is not fully elucidated.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
Adults: 200 mg IM or 100 mg PO or 200 mg PR every 6–8 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
12-15 hours; may be prolonged in hepatic impairment.
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Renal (30-50% as unchanged drug and metabolites), biliary/fecal (minor).
Category C
Category C
Antipsychotic (Phenothiazine) / Antiemetic
Antiemetic